Pharmaceutical

Reset Pharma partners with Filament to license psilocybin drug

Reset Pharma has entered a licensing agreement with Filament for psilocybin drug PEX010, designed for treating demoralisation syndrome.

Sep 1, 2023 - 20:00
Reset Pharma partners with Filament to license psilocybin drug
Reset Pharma has entered a licensing agreement with Filament for psilocybin drug PEX010, designed for treating demoralisation syndrome.
Read the original article

Tags:

Previous Article

The changing of the guard is expected in the Crohn’s disease marketplace

Next Article

Huadong enters licence deal for MC2 Therapeutics’ Wynzora cream

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

How Seth Rogen and Lauren Miller Rogen are using comedy to support Alzheimer’s care

How Seth Rogen and Lauren Miller Rogen are using comedy...

Sep 8, 2023

Access to new tools to combat RSV in babies likely to prove challenging

Access to new tools to combat RSV in babies likely to p...

Oct 6, 2023

FDA extends review of GSK’s myelofibrosis drug

FDA extends review of GSK’s myelofibrosis drug

Jun 19, 2023